Lisuride

Direct ergoline dopamine agonist (D1-D5) that bypasses the cardiac valvulopathy problem of pergolide/cabergoline by being a 5-HT2B silent antagonist — a real and elegant pharmacological feature. Used in EU as a Parkinson's adjunct (oral, transdermal, subcutaneous infusion) and for hyperprolactinemia/migraine; off-market in the US, available only as a research chemical (IdeaLabs liquid). For Dylan: SKIP-FOR-NOW. Direct dopamine agonism carries class-level impulse-control-disorder risk (gambling, hypersexuality, compulsive behaviors) that is not negotiated away by 5-HT2B cleanness, plus brain-development concerns at 20 and zero pressing problem this compound solves that bromantane, selegiline, or BPAP do not solve more safely.

Dopaminergic — direct full agonist across all five receptors

Lisuride is a high-affinity, non-selective dopamine receptor agonist that hits every DA receptor subtype:

• D2 / D3: sub-nanomolar Ki — this is where the Parkinson's and prolactin-lowering efficacy comes from
• D1 / D4 / D5: low-nanomolar — meaningful direct postsynaptic D1 stimulation distinguishes lisuride from D2-preferring agonists like pramipexole/ropinirole
• Acts as a partial agonist at D2/D3/D4 (still high efficacy clinically), full agonist at D1/D5

This matters for two reasons:

1. Direct postsynaptic stimulation bypasses presynaptic regulation. Unlike compounds that work upstream (selegiline preserving endogenous DA, bromantane upregulating tyrosine hydroxylase, BPAP amplifying impulse-evoked release via TAAR1), a direct agonist drives the postsynaptic receptor regardless of what the firing neuron is doing. The effect is not physiologically gated.
2. Class-level ICD risk attaches to direct DA agonism, not to lisuride specifically. Pathological gambling, hypersexuality, compulsive shopping/eating, punding — these are documented across pramipexole, ropinirole, rotigotine, bromocriptine, cabergoline, and lisuride. The receptor pharmacology that drives the therapeutic effect is the same pharmacology that drives the impulse dysregulation.

Serotonergic — the part that makes lisuride distinct from its ergoline siblings

• 5-HT2B: silent antagonist (this is the headline feature). 5-HT2B agonism on cardiac valve interstitial cells drives mitogenic signaling → fibrotic valvulopathy. This is what killed pergolide and benched cabergoline at antiparkinsonian doses. Lisuride actively blocks 5-HT2B, and the pharmacovigilance record bears this out — no signal of valvulopathy across roughly 360,000 patient-years of use.
• 5-HT2A: partial agonist with low Gq efficacy (~6-52% Emax). Lisuride is structurally an LSD analog and binds 5-HT2A with high affinity, yet is not psychedelic at clinical doses. The 2023-2025 mechanistic literature (Roth lab, Olson lab, others) has converged on a model where psychedelic effect requires Gq Emax above some threshold (~70%) plus β-arrestin recruitment plus Egr-1/Egr-2 induction — lisuride sits below the threshold on Gq, fails to induce Egr-1/Egr-2, and additionally its potent 5-HT1A agonism functionally counter-regulates 5-HT2A signaling.
• 5-HT1A / 5-HT1B / 5-HT1D: full or near-full agonist. 5-HT1A agonism contributes to anxiolysis but also to the non-psychedelic profile.
• 5-HT2C: partial agonist. Implicated in sleep/circadian effects (some users report better sleep timing).
• 5-HT5A, 5-HT6, 5-HT7: various partial agonist / antagonist profile depending on the assay.

Other receptors

• H1 (histamine): partial agonist — does not produce the classic H1-blockade sedation of antihistamines, but can cause mild drowsiness.
• α1A / α2A / α2B / α2C adrenergic: silent antagonist — contributes to orthostatic hypotension and the nausea/dizziness onset.

Net pharmacological identity

Lisuride is the most "polypharmacological" of the dopamine agonists in clinical use. The 5-HT2B antagonism is the clean differentiator that makes it the only ergoline currently considered cardiac-safe; the 5-HT1A agonism + low-Gq 5-HT2A partial agonism explains its non-psychedelic profile despite LSD-analog structure; the broad DA receptor coverage is both its therapeutic strength and its ICD risk.

Pharmacokinetics

• Half-life: ~2 hours (short — drives multiple-daily-dose Parkinson's regimens and the appeal of subcutaneous infusion / transdermal patch in advanced PD)
• Oral bioavailability: Poor (low double digits) and highly variable between individuals — peak plasma at 60-80 min post-dose
• Plasma protein binding: 60-70%
• Metabolism: Hepatic; CYP3A4 implicated (clinical relevance for grapefruit / itraconazole / strong CYP3A4 inhibitors)
• Long-tailed receptor effects: Despite the short plasma half-life, several effects (especially 5-HT2B antagonism, prolactin suppression) persist far longer than plasma exposure — the molecule appears to bind some receptors quasi-irreversibly. This is exploited in the bioenergetic-forum protocols of infrequent dosing.